Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

APC truncating mutations in Middle Eastern Population: Tankyrase inhibitor is an effective strategy to sensitize APC mutant CRC To 5-FU chemotherapy.

Siraj AK, Kumar Parvathareddy S, Pratheeshkumar P, Padmaja Divya S, Ahmed SO, Melosantos R, Begum R, Concepcion RMJA, Al-Sanea N, Ashari LH, Abduljabbar A, Al-Dayel F, Al-Kuraya KS.

Biomed Pharmacother. 2020 Jan;121:109572. doi: 10.1016/j.biopha.2019.109572. Epub 2019 Nov 5.

2.

Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population.

Siraj AK, Bu R, Iqbal K, Parvathareddy SK, Siraj N, Siraj S, Diaz MRF, Rala DR, Benito AD, Sabido MA, Al-Rasheed M, Al-Obaisi KAS, Al-Haqawi W, Victoria IG, Al Balawy W, Abedalthagafi M, Wakil SM, Ajarim D, Mohammed S, Alhussain T, Tulbah A, Al-Badawi IA, Al-Dayel F, Al-Kuraya KS.

Genomics. 2019 Oct 30. pii: S0888-7543(19)30404-5. doi: 10.1016/j.ygeno.2019.09.017. [Epub ahead of print]

3.

Whole-Exome Sequencing of Matched Primary and Metastatic Papillary Thyroid Cancer.

Masoodi T, Siraj AK, Siraj S, Azam S, Qadri Z, Albalawy WN, Parvathareddy SK, Al-Sobhi SS, Al-Dayel F, Alkuraya FS, Al-Kuraya KS.

Thyroid. 2019 Dec 4. doi: 10.1089/thy.2019.0052. [Epub ahead of print]

PMID:
31668133
4.

Prognostic significance of DNMT3A alterations in Middle Eastern papillary thyroid carcinoma.

Siraj AK, Pratheeshkumar P, Parvathareddy SK, Bu R, Masoodi T, Iqbal K, Al-Rasheed M, Al-Dayel F, Al-Sobhi SS, Alzahrani AS, Al-Dawish M, Al-Kuraya KS.

Eur J Cancer. 2019 Aug;117:133-144. doi: 10.1016/j.ejca.2019.05.025. Epub 2019 Jul 4.

PMID:
31280122
5.

TGFβ-induced SMAD4-dependent Apoptosis Proceeded by EMT in CRC.

Siraj AK, Pratheeshkumar P, Divya SP, Parvathareddy SK, Bu R, Masoodi T, Kong Y, Thangavel S, Al-Sanea N, Ashari LH, Abduljabbar A, Al-Homoud S, Al-Dayel F, Al-Kuraya KS.

Mol Cancer Ther. 2019 Jul;18(7):1312-1322. doi: 10.1158/1535-7163.MCT-18-1378. Epub 2019 May 3.

PMID:
31053577
6.

Prevalence, spectrum, and founder effect of BRCA1 and BRCA2 mutations in epithelial ovarian cancer from the Middle East.

Siraj AK, Bu R, Iqbal K, Siraj N, Al-Haqawi W, Al-Badawi IA, Parvathareddy SK, Masoodi T, Tulbah A, Al-Dayel F, Al-Kuraya KS.

Hum Mutat. 2019 Jun;40(6):729-733. doi: 10.1002/humu.23736. Epub 2019 Mar 18.

PMID:
30825404
7.

Overexpression of PARP is an independent prognostic marker for poor survival in Middle Eastern breast cancer and its inhibition can be enhanced with embelin co-treatment.

Siraj AK, Pratheeshkumar P, Parvathareddy SK, Divya SP, Al-Dayel F, Tulbah A, Ajarim D, Al-Kuraya KS.

Oncotarget. 2018 Dec 18;9(99):37319-37332. doi: 10.18632/oncotarget.26470. eCollection 2018 Dec 18.

8.

Spectrum of the KIT Gene Mutations in Gastrointestinal Stromal Tumors in Arab Patients

Faiyaz-Ul-Haque M, Al-Dayel F, Tulba A, Abalkhail H, Alhussaini H, Memon M, Bazarbashi S, Amin T, Satti MB, Peltekova I, Nawaz Z, Zaidi SH.

Asian Pac J Cancer Prev. 2018 Oct 26;19(10):2905-2910.

9.

FoxM1 is an independent poor prognostic marker and therapeutic target for advanced Middle Eastern breast cancer.

Siraj AK, Pratheeshkumar P, Parvathareddy SK, Qadri Z, Thangavel S, Ahmed S, Al-Dayel F, Tulbah A, Ajarim D, Al-Kuraya KS.

Oncotarget. 2018 Apr 3;9(25):17466-17482. doi: 10.18632/oncotarget.24739. eCollection 2018 Apr 3.

10.

FoxM1 and β-catenin predicts aggressiveness in Middle Eastern ovarian cancer and their co-targeting impairs the growth of ovarian cancer cells.

Pratheeshkumar P, Divya SP, Parvathareddy SK, Alhoshani NM, Al-Badawi IA, Tulbah A, Al-Dayel F, Siraj AK, Al-Kuraya KS.

Oncotarget. 2017 Dec 16;9(3):3590-3604. doi: 10.18632/oncotarget.23338. eCollection 2018 Jan 9.

11.

Downregulation of SKP2 in Papillary Thyroid Cancer Acts Synergistically With TRAIL on Inducing Apoptosis via ROS.

Pratheeshkumar P, Siraj AK, Divya SP, Parvathareddy SK, Begum R, Melosantos R, Al-Sobhi SS, Al-Dawish M, Al-Dayel F, Al-Kuraya KS.

J Clin Endocrinol Metab. 2018 Apr 1;103(4):1530-1544. doi: 10.1210/jc.2017-02178.

PMID:
29300929
12.

Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer.

Bu R, Siraj AK, Divya SP, Kong Y, Parvathareddy SK, Al-Rasheed M, Al-Obaisi KAS, Victoria IG, Al-Sobhi SS, Al-Dawish M, Al-Dayel F, Al-Kuraya KS.

Int J Cancer. 2018 May 15;142(10):2028-2039. doi: 10.1002/ijc.31225. Epub 2017 Dec 29.

13.

Saudi lung cancer management guidelines 2017.

AR Jazieh on Behalf of Saudi Lung Cancer Guidelines Association, Saudi Lung Cancer Guidelines Members, Jazieh AR, Al Kattan K, Bamousa A, Al Olayan A, Abdelwarith A, Ansari J, Al Twairqi A, Al Fayea T, Al Saleh K, Al Husaini H, Abdelhafiez N, Mahrous M, Faris M, Al Omair A, Hebshi A, Al Shehri S, Al Dayel F, Bamefleh H, Khalbuss W, Al Ghanem S, Loutfi S, Khankan A, Al Rujaib M, Al Ghamdi M, Ibrahim N, Swied A, Al Kayait M, Datario M.

Ann Thorac Med. 2017 Oct-Dec;12(4):221-246. doi: 10.4103/atm.ATM_92_17.

14.

Expanding the spectrum of germline variants in cancer.

Siraj AK, Masoodi T, Bu R, Parvathareddy SK, Al-Badawi IA, Al-Sanea N, Ashari LH, Abduljabbar A, Alhomoud S, Al-Sobhi SS, Tulbah A, Ajarim D, Alzoman K, Aljuboury M, Yousef HB, Al-Dawish M, Al-Dayel F, Alkuraya FS, Al-Kuraya KS.

Hum Genet. 2017 Nov;136(11-12):1431-1444. doi: 10.1007/s00439-017-1845-0. Epub 2017 Oct 3.

PMID:
28975465
15.

XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis.

Hussain AR, Siraj AK, Ahmed M, Bu R, Pratheeshkumar P, Alrashed AM, Qadri Z, Ajarim D, Al-Dayel F, Beg S, Al-Kuraya KS.

BMC Cancer. 2017 Sep 11;17(1):640. doi: 10.1186/s12885-017-3627-4.

16.

MED12 is recurrently mutated in Middle Eastern colorectal cancer.

Siraj AK, Masoodi T, Bu R, Pratheeshkumar P, Al-Sanea N, Ashari LH, Abduljabbar A, Alhomoud S, Al-Dayel F, Alkuraya FS, Al-Kuraya KS.

Gut. 2018 Apr;67(4):663-671. doi: 10.1136/gutjnl-2016-313334. Epub 2017 Feb 9.

17.

Reference intervals for common biochemistry laboratory tests in the Saudi population by a direct a priori method.

Hu XL, Hassan H, Al-Dayel FH.

Ann Saudi Med. 2017 Jan-Feb;37(1):16-20. doi: 10.5144/0256-4947.2017.16.

18.

Testing for ROS1 in non-small cell lung cancer: a review with recommendations.

Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E.

Virchows Arch. 2016 Nov;469(5):489-503. Epub 2016 Aug 17. Review.

19.

Genomic Profiling of Thyroid Cancer Reveals a Role for Thyroglobulin in Metastasis.

Siraj AK, Masoodi T, Bu R, Beg S, Al-Sobhi SS, Al-Dayel F, Al-Dawish M, Alkuraya FS, Al-Kuraya KS.

Am J Hum Genet. 2016 Jun 2;98(6):1170-1180. doi: 10.1016/j.ajhg.2016.04.014. Epub 2016 May 26.

20.

Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis.

Bu R, Siraj AK, Al-Obaisi KA, Beg S, Al Hazmi M, Ajarim D, Tulbah A, Al-Dayel F, Al-Kuraya KS.

Int J Cancer. 2016 Sep 1;139(5):1091-7. doi: 10.1002/ijc.30143. Epub 2016 May 3.

21.

ALK alteration is a frequent event in aggressive breast cancers.

Siraj AK, Beg S, Jehan Z, Prabhakaran S, Ahmed M, R Hussain A, Al-Dayel F, Tulbah A, Ajarim D, Al-Kuraya KS.

Breast Cancer Res. 2015 Sep 17;17:127. doi: 10.1186/s13058-015-0610-3.

22.

Molecular markers and pathway analysis of colorectal carcinoma in the Middle East.

Beg S, Siraj AK, Prabhakaran S, Bu R, Al-Rasheed M, Sultana M, Qadri Z, Al-Assiri M, Sairafi R, Al-Dayel F, Al-Sanea N, Uddin S, Al-Kuraya KS.

Cancer. 2015 Nov 1;121(21):3799-808. doi: 10.1002/cncr.29580. Epub 2015 Jul 28.

23.

Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells.

Ahmed M, Hussain AR, Siraj AK, Uddin S, Al-Sanea N, Al-Dayel F, Al-Assiri M, Beg S, Al-Kuraya KS.

Mol Cancer. 2015 Jul 10;14:131. doi: 10.1186/s12943-015-0406-1.

24.

Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.

Hussain AR, Al-Romaizan M, Ahmed M, Thangavel S, Al-Dayel F, Beg S, Uddin S, Siraj AK, Al-Kuraya KS.

Mol Med. 2015 May 26;21:466-78. doi: 10.2119/molmed.2014.00238.

25.

PTEN loss is associated with follicular variant of Middle Eastern papillary thyroid carcinoma.

Beg S, Siraj AK, Jehan Z, Prabakaran S, Al-Sobhi SS, Al-Dawish M, Al-Dayel F, Al-Kuraya KS.

Br J Cancer. 2015 Jun 9;112(12):1938-43. doi: 10.1038/bjc.2015.169. Epub 2015 May 19.

26.

Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer.

Beg S, Siraj AK, Prabhakaran S, Jehan Z, Ajarim D, Al-Dayel F, Tulbah A, Al-Kuraya KS.

Breast Cancer Res Treat. 2015 Jun;151(3):541-53. doi: 10.1007/s10549-015-3430-3. Epub 2015 May 16.

PMID:
25981902
27.

Role of X-Linked Inhibitor of Apoptosis as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma.

Hussain AR, Bu R, Ahmed M, Jehan Z, Beg S, Al-Sobhi S, Al-Dayel F, Siraj AK, Uddin S, Al-Kuraya KS.

J Clin Endocrinol Metab. 2015 Jul;100(7):E974-85. doi: 10.1210/jc.2014-4356. Epub 2015 May 14.

PMID:
25974735
28.

Prevalence of Lynch syndrome in a Middle Eastern population with colorectal cancer.

Siraj AK, Prabhakaran S, Bavi P, Bu R, Beg S, Hazmi MA, Al-Rasheed M, Al-Assiri M, Sairafi R, Al-Dayel F, Al-Sanea N, Uddin S, Al-Kuraya KS.

Cancer. 2015 Jun 1;121(11):1762-71. doi: 10.1002/cncr.29288. Epub 2015 Feb 24.

29.

Control of histone H3 phosphorylation by CaMKIIδ in response to haemodynamic cardiac stress.

Awad S, Al-Haffar KM, Marashly Q, Quijada P, Kunhi M, Al-Yacoub N, Wade FS, Mohammed SF, Al-Dayel F, Sutherland G, Assiri A, Sussman M, Bers D, Al-Habeeb W, Poizat C.

J Pathol. 2015 Mar;235(4):606-18. doi: 10.1002/path.4489. Epub 2014 Dec 17.

30.

A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma.

Siraj AK, Bu R, Prabhakaran S, Bavi P, Beg S, Al Hazmi M, Al-Rasheed M, Alobaisi K, Al-Dayel F, AlManea H, Al-Sanea N, Uddin S, Al-Kuraya KS.

Mol Cancer. 2014 Jul 8;13:168. doi: 10.1186/1476-4598-13-168.

31.

High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.

Ahmed M, Hussain AR, Bavi P, Ahmed SO, Al Sobhi SS, Al-Dayel F, Uddin S, Al-Kuraya KS.

Carcinogenesis. 2014 Jul;35(7):1564-72. doi: 10.1093/carcin/bgu051. Epub 2014 Feb 28.

PMID:
24583924
32.

Ovarian angiosarcoma: a case report and review of the literature.

Yaqoob N, Nemenqani D, Khoja H, Hafez M, Tulbah A, Al-Dayel F.

J Med Case Rep. 2014 Feb 12;8:47. doi: 10.1186/1752-1947-8-47.

33.

The journey toward personalized cancer therapy.

Tulbah A, Chaudhri N, Al Dayel F, Akhtar M.

Adv Anat Pathol. 2014 Jan;21(1):36-43. doi: 10.1097/PAP.0000000000000006. Review.

PMID:
24316909
34.

ALK gene amplification is associated with poor prognosis in colorectal carcinoma.

Bavi P, Jehan Z, Bu R, Prabhakaran S, Al-Sanea N, Al-Dayel F, Al-Assiri M, Al-Halouly T, Sairafi R, Uddin S, Al-Kuraya KS.

Br J Cancer. 2013 Nov 12;109(10):2735-43. doi: 10.1038/bjc.2013.641. Epub 2013 Oct 15.

35.

Phosphorylated IκBα predicts poor prognosis in activated B-cell lymphoma and its inhibition with thymoquinone induces apoptosis via ROS release.

Hussain AR, Uddin S, Ahmed M, Al-Dayel F, Bavi PP, Al-Kuraya KS.

PLoS One. 2013;8(3):e60540. doi: 10.1371/journal.pone.0060540. Epub 2013 Mar 28.

36.

EGFR mutation testing in non-small cell lung cancer (NSCLC).

Al Dayel F.

J Infect Public Health. 2012 Dec;5 Suppl 1:S31-4. doi: 10.1016/j.jiph.2012.09.008. Epub 2012 Nov 4.

37.

Clinico-pathological significance of TNF alpha-induced protein3 (TNFAIP3) in Middle Eastern colorectal carcinoma.

Bavi P, Abubaker J, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Siraj AK, Al-Kuraya KS.

Clin Epigenetics. 2011 Aug;2(2):417-8. doi: 10.1007/s13148-011-0049-z. Epub 2011 Jul 14. No abstract available.

38.

Colorectal cancer risk is not associated with increased levels of homozygosity in Saudi Arabia.

Siraj AK, Khalak HG, Sultana M, Al-Rasheed M, Bavi P, Al-Sanea N, Al-Dayel F, Uddin S, Alkuraya FS, Al-Kuraya KS.

Genet Med. 2013;14(8):720-728. doi: 10.1038/gim.2012.27. Epub 2012 Apr 5.

PMID:
22481135
39.

Role of nuclear factor-κB regulators TNFAIP3 and CARD11 in Middle Eastern diffuse large B-cell lymphoma.

Bu R, Bavi P, Abubaker J, Jehan Z, Al-Haqawi W, Ajarim D, Al-Dayel F, Uddin S, Al-Kuraya KS.

Leuk Lymphoma. 2012 Oct;53(10):1971-7. doi: 10.3109/10428194.2012.668286. Epub 2012 Apr 18.

PMID:
22397314
40.

Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma.

Uddin S, Hussain AR, Ahmed M, Siddiqui K, Al-Dayel F, Bavi P, Al-Kuraya KS.

Haematologica. 2012 Jul;97(7):1092-100. doi: 10.3324/haematol.2011.053421. Epub 2012 Jan 22.

41.

c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce papillary thyroid carcinoma cell death.

Bu R, Uddin S, Ahmed M, Hussain AR, Alsobhi S, Amin T, Al-Nuaim A, Al-Dayel F, Abubaker J, Bavi P, Al-Kuraya KS.

Mol Med. 2012 Mar 27;18:167-77. doi: 10.2119/molmed.2011.00238.

42.

FoxM1 and its association with matrix metalloproteinases (MMP) signaling pathway in papillary thyroid carcinoma.

Ahmed M, Uddin S, Hussain AR, Alyan A, Jehan Z, Al-Dayel F, Al-Nuaim A, Al-Sobhi S, Amin T, Bavi P, Al-Kuraya KS.

J Clin Endocrinol Metab. 2012 Jan;97(1):E1-E13. doi: 10.1210/jc.2011-1506. Epub 2011 Nov 2.

PMID:
22049175
43.

Coexpression of activated c-Met and death receptor 5 predicts better survival in colorectal carcinoma.

Uddin S, Hussain AR, Ahmed M, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Bavi P, Al-Kuraya KS.

Am J Pathol. 2011 Dec;179(6):3032-44. doi: 10.1016/j.ajpath.2011.08.007. Epub 2011 Oct 5.

44.

Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma.

Bavi P, Uddin S, Ahmed M, Jehan Z, Bu R, Abubaker J, Sultana M, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Prabhakaran S, Hussain AR, Al-Kuraya KS.

Am J Pathol. 2011 May;178(5):2109-20. doi: 10.1016/j.ajpath.2011.01.034.

45.

The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).

Bavi P, Uddin S, Bu R, Ahmed M, Abubaker J, Balde V, Qadri Z, Ajarim D, Al-Dayel F, Hussain AR, Al-Kuraya KS.

J Pathol. 2011 Jul;224(3):355-66. doi: 10.1002/path.2864. Epub 2011 Apr 19.

PMID:
21506127
46.

Overexpression of fatty acid synthase in Middle Eastern epithelial ovarian carcinoma activates AKT and Its inhibition potentiates cisplatin-induced apoptosis.

Uddin S, Jehan Z, Ahmed M, Alyan A, Al-Dayel F, Hussain A, Bavi P, Al-Kuraya KS.

Mol Med. 2011;17(7-8):635-45. doi: 10.2119/molmed.2011.00046. Epub 2011 Mar 21.

47.

Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy.

Uddin S, Ahmed M, Hussain A, Abubaker J, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Jehan Z, Bavi P, Siraj AK, Al-Kuraya KS.

Am J Pathol. 2011 Feb;178(2):537-47. doi: 10.1016/j.ajpath.2010.10.020.

48.

Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations.

Bavi P, Prabhakaran SE, Abubaker J, Qadri Z, George T, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Hussain AR, Uddin S, Al-Kuraya KS.

Mol Cancer. 2010 Jul 30;9:203. doi: 10.1186/1476-4598-9-203.

49.

HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma.

Bu R, Uddin S, Bavi P, Hussain AR, Al-Dayel F, Ghourab S, Ahmed M, Al-Kuraya KS.

Lab Invest. 2011 Jan;91(1):124-37. doi: 10.1038/labinvest.2010.136. Epub 2010 Jul 26.

50.

Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling.

Hussain AR, Uddin S, Ahmed M, Bu R, Ahmed SO, Abubaker J, Sultana M, Ajarim D, Al-Dayel F, Bavi PP, Al-Kuraya KS.

J Pathol. 2010 Oct;222(2):180-90. doi: 10.1002/path.2747.

PMID:
20632385

Supplemental Content

Loading ...
Support Center